lobbying_activities: 3007649

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3007649	792182d8-1de6-4d73-8e21-7b44be27a39a	Q2	IGM BIOSCIENCES, INC.	401106312	IGM BIOSCIENCES, INC.	2023	second_quarter	MED	COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act	Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		230000	0	0	2023-07-17T15:21:17-04:00